Project Grant R41DA047865

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $810,668 to Virogenomics Biodevelopment, Inc. to evaluate an immunotherapeutic compound called DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The key objectives of this one-year project are to assess DRHQ's impact on drug-seeking behavior, cognitive function, and inflammation in preclinical...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $3,287,052 to Virogenomics Biodevelopment, Inc. to advance the development of the CD74-targeting compound DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The key objectives of this project are to conduct IND-enabling studies and a Phase I clinical trial to evaluate the safety of DRHQ in both...

The National Institute on Drug Abuse (NIDA) awarded Myosin Therapeutics Inc. a $2,916,991 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to support a Phase 1B clinical trial of their novel therapeutic agent MT-110. The trial will assess the safety and tolerability of single ascending doses of MT-110 in individuals with methamphetamine use disorder (MUD), a condition affecting an estimated 4 million people in the U.S. with high relapse rates. The study aims to determine...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $634,048 to The University of Kentucky Research Foundation to conduct a human laboratory study advancing the development of troriluzole as a potential treatment for methamphetamine use disorder (MUD), both alone and in comorbidity with opioid use disorder (OUD). The key products and services to be delivered include: 1) assessing the reinforcing...

This Cooperative Agreement award, valued at $2,983,510.00 and issued by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to assess the efficacy of deep transcranial magnetic stimulation (dTMS) in modulating neural circuits associated with methamphetamine use disorder (MUD) and reducing relapse risk. The project will be conducted in two phases. In the UG3 phase, the researchers will enroll 30 participants with MUD to determine if...

This $804,728 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to investigate the role of the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 (cysLT-cysLTR1) axis in promoting HIV persistence and brain injury in the presence of methamphetamine (meth) and combination antiretroviral therapy (cART). The research will utilize in vitro and in vivo approaches, including single-cell and single-nuclei RNA...

This $11,811,988 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the CFDA 93.279 Drug Use and Addiction Research Programs, supports the development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing opioid relapse and overdose. The award to the University of Texas Health Science Center at San Antonio aims to: 1) submit an Investigational New Drug (IND) application for MCAM, 2) complete Phase 1 and 1b clinical trials, 3) plan a Phase...

This Project Grant awarded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop novel small molecule therapeutics for the safe and effective treatment of Opioid Use Disorder (OUD). The $399,414 award will fund the development of an AI-powered drug discovery platform called M3.AI, which will integrate target-based and phenotype-based methodologies to identify new polypharmacological lead compounds. The platform will...

The National Institute on Drug Abuse (NIDA) awarded a $139,000 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Temple University to investigate the ability of the chemokine receptor antagonist AMD3100 to reduce heroin self-administration and relapse behaviors in animal models. The researchers will examine the role of the chemokine receptor CXCR4 in dopaminergic neurons within the ventral tegmental area in modifying heroin taking behaviors. This work aims to...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to generate synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel multi-target compounds for the treatment of substance use disorders (SUDs). The $399,483 project, awarded on May 15, 2025, with an expected completion by April 30, 2026, will focus on screening DEL libraries of 125 million compounds...